SCHEMBL320899

SCHEMBL320899

COc1cc(O)cc(OC)c1C

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.64
MAPT P10636 1/20 0.64
PTGS2 P35354 6/20 0.54
ALOX5 P09917 5/20 0.54
MAOB P27338 1/20 0.52
TDP1 Q9NUW8 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
CYP1A1 P04798 1/20 0.42
PTGS1 P23219 1/20 0.42
ALDH1A1 P00352 1/20 0.41
TTR P02766 1/20 0.41
APP P05067 1/20 0.41
ACHE P22303 1/20 0.40
SYNJ2 O15056 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL683246 0.87 CYP3A4 (0.56) CYP3A4MAPTPTGS2ALOX5MAOB
SCHEMBL69301 0.87 CYP3A4 (0.56) CYP3A4MAPTPTGS2ALOX5MAOB
Methoxymethane SCHEMBL28032536 0.85 CYP3A4 (0.54) CYP3A4MAPTPTGS2ALOX5MAOB
SCHEMBL14951058 0.84 CYP3A4 (0.52) CYP3A4MAPTPTGS2ALOX5MAOB
SCHEMBL28618565 0.83 CYP3A4 (0.47) CYP3A4MAPTPTGS2ALOX5MAOB
SCHEMBL28962160 0.80 TTR (0.49) CYP3A4MAPTMAOBMEN1KMT2A
SCHEMBL70379 0.80 ALOX5 (0.70) CYP3A4MAPTPTGS2ALOX5MAOB
SCHEMBL8064768 0.80 CYP3A4 (0.67) CYP3A4MAPTPTGS2ALOX5MAOB
Antiarol SCHEMBL210578 0.78 CYP3A4 (1.00) CYP3A4MAPTPTGS2ALOX5MAOB
Ethane SCHEMBL27660205 0.78 ALOX5 (0.67) CYP3A4MAPTPTGS2ALOX5MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250367137-A1 Phloroglucinol Formulations And Methods Of Use CINPHLORO PHARMA LLC (US) 2025-12-04 US claimed
US-20250177320-A1 PHARMACEUTICAL FORMULATIONS OF PHLOROGLUCINOL AND TRIMETHYLPHLOROGLUCINOL CINRX PHARMA, LLC (US) 2025-06-05 US claimed
CN-120064530-A Application of magnetic solid-phase dispersion extractant in detection of mycotoxin content in wheat 南昌大学 2025-05-30 CN claimed
CN-119574738-A Method for detecting related substances in trimethylphloroglucinol 河北广祥制药有限公司 2025-03-07 CN claimed
CN-119367285-A Preparation method and application of phloroglucinol injection 北京科源创欣科技有限公司 2025-01-28 CN claimed
CN-119325372-A Phloroglucinol formulations and methods of use 辛菲特罗制药有限公司 2025-01-17 CN claimed
CN-119241339-A Trimethyl room preparation method of phloroglucinol 河北广祥制药有限公司 2025-01-03 CN claimed
CN-114583262-B Electrolyte and lithium ion battery 比亚迪股份有限公司 2024-10-11 CN claimed
CN-114890871-B Preparation method of crude trimethylphloroglucinol and preparation method of trimethylphloroglucinol 海口天行健药物研究有限公司 2024-09-17 CN claimed
CN-118615874-A Preparation method and ion separation application of post-modified COF@dopamine composite membrane 三峡大学 2024-09-10 CN claimed
CN-112535659-A Preparation method of phloroglucinol injection 南京艾德凯腾生物医药有限责任公司 2021-03-23 CN claimed
CN-112516077-A Phloroglucinol injection and preparation method thereof 万邦德制药集团有限公司 2021-03-19 CN claimed
CN-111840259-A Injection of phloroglucinol and trimethyl phloroglucinol and preparation method thereof 武汉人福药业有限责任公司 2020-10-30 CN claimed
WO-2018165404-A1 PHARMACEUTICAL FORMUALTIONS OF PHLOROGLUCINOL AND TRIMETHYLPHLOROGLUCINOL CINRX PHARMA, LLC (US) 2018-09-13 WO claimed
US-20150150953-A1 PHARMACEUTICAL COMPOSITION ADAPTED FOR ORAL ADMINISTRATION AND THE PROCESS FOR ITS PREPARATION, FOR THE PREVENTION AND TREATMENT OF IRRITABLE BOWEL SYNDROME, BASED ON AN INTESTINAL MOTILITY MODIFIER AND a-D-GALACTOSIDASE POSI VISIONARY SOLUTIONS LLP (GB) 2015-06-04 US claimed
EP-2790689-A1 TREATMENT OF MIGRAINE HEADACHES, IN PARTICULAR CLUSTER HEADACHES Pharmeuro (LU) 2014-10-22 EP claimed
US-20130344145-A1 ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER, AN AGENT THAT PREVENTS GAS RETENTION, AND DIGESTIVE ENZYMES, AND PREPARATION METHOD THEREOF POSI VISIONARY SOLUTIONS LLP (GB) 2013-12-26 US claimed
EP-2641598-A2 ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER, AN AGENT THAT PREVENTS GAS RETENTION, AND DIGESTIVE ENZYMES, AND PREPARATION METHOD THEREOF Posi Visionary Solutions LLP (GB) 2013-09-25 EP claimed
EP-2641968-A2 ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF, FOR THE PREVENTION AND TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER AND -D-GALACTOSIDASE Posi Visionary Solutions LLP (GB) 2013-09-25 EP claimed
WO-2013087410-A1 TREATMENT OF MIGRAINE HEADACHES, IN PARTICULAR CLUSTER HEADACHES PHARMEURO (LU) 2013-06-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250367137-A1 Phloroglucinol Formulations And Methods Of Use MLN, HRH2, PYGM CYP3A4 266/4885MAPT 1581/4885PTGS2 215/4885
US-20250177320-A1 PHARMACEUTICAL FORMULATIONS OF PHLOROGLUCINOL AND TRIMETHYLPHLOROGLUCINOL SLC5A2, SLC5A1, LCT CYP3A4 386/4885MAPT 559/4885PTGS2 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.